Celldex to stop skin disease study after trial setback

Impact · against what's priced in

Celldex Therapeutics faces a valuation hit following the total abandonment of an experimental skin disease drug. The discontinuation after failing mid-stage trial goals removes a potential future revenue stream from the company's pipeline.

CLDX−0.80: No priced-in read yet
In context: The company is discontinuing a drug candidate after it failed to meet primary and key secondary goals in a mid-stage study, representing a loss of potential future revenue.
Read from the article alone

Celldex to stop skin disease study after trial setback

biotech
CLDX
clinical trial
dermatology
drug failure

Search tags

Celldex to stop skin disease study after trial setback

What matters in this story

How each ticker is affected

TransMedics: 2027 Setting Up To Be A Pivotal Year

Celldex to stop skin disease study after trial setback

What matters in this story

How each ticker is affected

TransMedics: 2027 Setting Up To Be A Pivotal Year

Track these names every morning.

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

Celldex to stop skin disease study after trial setback

What matters in this story

How each ticker is affected

Next reads from the same story arc

TransMedics: 2027 Setting Up To Be A Pivotal Year

Celldex to stop skin disease study after trial setback

What matters in this story

How each ticker is affected

Next reads from the same story arc

TransMedics: 2027 Setting Up To Be A Pivotal Year

Track these names every morning.

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track